Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Certolizumab Pegol Clear all
Completed Phase 3 Interventional

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00160602
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Montgomery, Alabama • Sun City West, Arizona • Palm Desert, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 25, 2026, 5:46 PM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

NCT06028438
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Nipocalimab, Certolizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Huntington Beach, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 25, 2026, 5:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

NCT00160706
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

NCT03357471
View directory record Official record
Conditions
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions
e-Device
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

NCT00753454
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

NCT01087788
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas

NCT01145365
View directory record Official record
Conditions
Crohns Disease, Fistula, Abscess
Interventions
Exam under anesthesia (EUA)
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 25, 2026, 5:46 PM EDT
Completed No phase listed Observational Results available

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

NCT00844285
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cimzia
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
197
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 25, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

NCT04991025
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
Interventions
Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Certolizumab, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

NCT00152386
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CDP870)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

NCT01500278
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
Biological · Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 25, 2026, 5:46 PM EDT
Completed No phase listed Observational

Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

NCT01098201
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2015 · Synced Sep 25, 2026, 5:46 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

NCT01190410
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Results available

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

NCT02019602
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions
Blood sampling from mother, Blood sampling from infant, Blood sampling from umbilical cord, Certolizumab Pegol
Procedure · Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Oklahoma City, Oklahoma • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 25, 2026, 5:46 PM EDT
Completed No phase listed Observational

Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

NCT05320159
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

NCT01053559
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 25, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 25, 2026, 5:46 PM EDT